Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

Experimental drug outperforms standard first-line therapy for advanced kidney cancer patients

HIF-2 inhibitors could be promising target to combat kidney cancer

HIF-2 inhibitors could be promising target to combat kidney cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Popular kidney cancer drugs do not reduce incidence of recurrence

Popular kidney cancer drugs do not reduce incidence of recurrence

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Therapy change significantly improves treatment outcomes for renal cell carcinoma patients

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison MediPharma begins sulfatinib Phase I trial in US

New clinical trial uses aggressive treatment method for patients with pancreas cancer

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Poorly-designed animal study threatens validity of preclinical research

Poorly-designed animal study threatens validity of preclinical research

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer benefit from cabozantinib treatment

Tolerability benefits with sunitinib schedule switch

Tolerability benefits with sunitinib schedule switch

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

SNPs predict sunitinib outcome in mRCC

SNPs predict sunitinib outcome in mRCC